Sanofi reveals detailed timeframe for RSV candidate

Now that a new set of study data supports a possible treatment for RSV, Sanofi has laid out its plan for applying to regulatory authorities.

Photo: CHARLES PLATIAU/Reuters / X00217

Over the course of the first six months of 2022, Sanofi expects to submit the first regulatory application for marketing authorization for a possible treatment of respiratory syncytial virus (RSV) in infants.

In a press release, the company states that it has received results from a phase II/III trial of the drug nirsevimab, which supports the drug candidate.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs